Gene Therapy

RST-001 for Retinitis Pigmentosa

Phase 1 & 2
Waitlist Available
Research Sponsored by Allergan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Upbaseline to 24 months
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is testing an experimental treatment for macular degeneration. It is enrolling 12 patients total, 6 of which must have very poor vision in the study eye, and 6 of which must have vision ranging from poor to 20/200.

Eligible Conditions
  • Retinitis Pigmentosa


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Any Grade 3 or Greater Adverse Event (AE) Considered Related to RST-001.
Secondary outcome measures
Change in Ambulation
Change in Quality of Life
Visual Acuity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Group 1Experimental Treatment1 Intervention
Single intravitreal injection of RST-001

Find a site

Who is running the clinical trial?

AllerganLead Sponsor
781 Previous Clinical Trials
275,851 Total Patients Enrolled
1 Trials studying Retinitis Pigmentosa
21 Patients Enrolled for Retinitis Pigmentosa
AbbVieLead Sponsor
902 Previous Clinical Trials
487,051 Total Patients Enrolled
Hanh Badger, PharmDStudy Director
1 Previous Clinical Trials
80 Total Patients Enrolled

Media Library

RST-001 (Gene Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02556736 — Phase 1 & 2
Retinitis Pigmentosa Research Study Groups: Group 1
Retinitis Pigmentosa Clinical Trial 2023: RST-001 Highlights & Side Effects. Trial Name: NCT02556736 — Phase 1 & 2
RST-001 (Gene Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02556736 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there numerous facilities administering the experiment within this state?

"At present, 4 medical centres are recruiting for this trial. Dallas, San Francisco and Cincinnati have established locations where patients can participate in the study while other cities house additional potential sites of enrolment. To reduce travelling burdens it is recommended to choose the closest location available when enrolling."

Answered by AI

Is the recruitment process for this clinical trial currently underway?

" shows that this research project is no longer accepting participants, as the last update to its posting was made on September 9th 2022. Despite this trial being inactive, there are 51 other trials actively recruiting patients at present time."

Answered by AI

Who else is applying?

What state do they live in?
Puerto Rico
How old are they?
18 - 65
What site did they apply to?
Retina Foundation of the Southwest
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
~2 spots leftby Oct 2024